Accessibility Menu
Bausch + Lomb logo

Bausch + Lomb(TSX) BLCO

Market CapCA$8.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)-7%
5 YearN/A
1 Year+21%
1 Month+2%
CA$24.10
+1.18%
+0.28Today
Bausch + Lomb last closing stock price
MetricPriceDate
Last closeCAD 24.102026-08-31
Bausch + Lomb stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.46%CAD 23.992026-08-24
1 month+1.86%CAD 23.662026-07-31
3 month+16.99%CAD 20.602026-06-02
Year to date+2.77%CAD 23.452025-12-31
1 year+20.56%CAD 19.992025-08-29
3 year-1.27%CAD 24.412023-09-01
Since inception-6.59%CAD 25.502022-05-06

Bausch + Lomb Financials at a Glance

Market Cap

CA$8.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$5.32B

Net Income (TTM)

-$170.81M

EPS (TTM)

-CA$0.67

P/E Ratio

-35.79

Dividend

CA$0.00

Beta (Volatility)

0.95 (Low)

Price

CA$24.10

Volume

1,806

Open

CA$23.90

Previous Close

CA$24.10

Daily Range

CA$23.90 - CA$24.10

52-Week Range

CA$19.36 - CA$25.70

Estimated Earnings Date

Oct 28, 2026

BLCO News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bausch + Lomb

Bausch + Lomb Corporation is a global leader in eye health, providing a comprehensive range of products and services. The company operates in three primary segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical.

Products and Services
  • Wide selection of contact lenses and lens care solutions
  • Proprietary and generic ophthalmic medications for various conditions
  • Advanced surgical tools for cataract and retinal treatments
Growth Outlook
  • Revenue increased to CAD 1.39 billion in Q2 2026, up from CAD 1.24 billion in Q1 2026
  • Gross profit margin improved to 58.1% in Q2 2026, indicating operational efficiency
  • Strong demand for eye health products supports long-term growth potential
Financial Highlights
  • Net income for Q2 2026 was CAD -13.99 million, reflecting ongoing investment in R&D
  • Operating income margin of 8.2% in Q2 2026 shows potential for profitability
  • Current ratio of 1.55 indicates strong short-term financial health
Bausch + Lomb Corporation has established itself as a key player in the eye health industry, with a diverse portfolio that caters to various consumer needs. The recent revenue growth and improved gross profit margin highlight the company's operational efficiency and market demand. Despite facing challenges reflected in net income figures, the focus on research and development positions the company for future advancements and profitability. The strong current ratio suggests that Bausch + Lomb is well-equipped to manage its short-term obligations, making it an intriguing option for potential investors interested in the healthcare sector.
AI Generated • Aug 27, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

13,000

CEO

Brenton L. Saunders, MBA

Website

www.bausch.com

Headquarters

Vaughan, ON L4K 4B4, CA

BLCO Financials

Key Financial Metrics (TTM)

Gross Margin

57.23%

Operating Margin

7.14%

Net Income Margin

-3.21%

Return on Equity

-2.67%

Return on Capital

1.59%

Return on Assets

-1.23%

Earnings Yield

-2.79%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$8.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

357.17M

Volume

1.81K

Avg. Volume

1.95K

Financials (TTM)

Gross Profit

$2.96B

Operating Income

$593.95M

EBITDA

$989.91M

Operating Cash Flow

$458.31M

Capital Expenditure

-$317.80M

Free Cash Flow

$140.50M

Cash & ST Invst.

$367.00M

Total Debt

$5.12B

Bausch + Lomb Performance Analysis

Bausch + Lomb annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 4,905,383,9443.9%
20232023-12-31USD 5,595,802,15714.1%
20242024-12-31USD 6,563,485,94417.3%
20252025-12-31USD 7,127,568,9758.6%
Bausch + Lomb sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.2%
Q42025-12-319.7%
Q12026-03-31-11.7%
Q22026-06-3012.3%
Bausch + Lomb annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 0.02N/A
20232023-12-31USD -1.00N/A
20242024-12-31USD -1.2323.3%
20252025-12-31USD -1.4215.2%
Bausch + Lomb sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3055.6%
Q42025-12-31-100.0%
Q12026-03-31-25.0%
Q22026-06-3080.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.39B

+9.0%

Gross Profit

$809.65M

+7.5%

Gross Margin

58.11%

N/A

Market Cap

CA$8.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$654.44K

N/A

Employees

13,000

N/A

Net Income

-$13.99M

+77.4%

EBITDA

$216.91M

+146.5%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$367.00M

+38.0%

Total Debt

$5.12B

+3.1%

Accounts Receivable

$1.16B

+7.0%

Inventory

$999.00M

-4.9%

Long Term Debt

$5.07B

+2.9%

Short Term Debt

$43.00M

+53.6%

Return on Assets

-1.23%

N/A

Return on Invested Capital

3.17%

N/A

Free Cash Flow

$82.00M

+251.9%

Operating Cash Flow

$153.00M

+337.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BHC.TOBausch Health Companies Inc.
CA$8.79+0.11%
CURA.TOCuraleaf Holdings, Inc.
CA$13.40-0.37%
WELL.TOWELL Health Technologies Corp.
CA$4.28-1.38%
TLRY.TOTilray Brands, Inc.
CA$6.36-0.16%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About BLCO

What is the current price of Bausch + Lomb?

Bausch + Lomb is trading at CA$24.10 per share.

What is the 52-week range for Bausch + Lomb?

Over the past 52 weeks, Bausch + Lomb has traded between CA$19.36 and CA$25.70.

How much debt does Bausch + Lomb have?

As of the most recent reporting period, Bausch + Lomb reported total debt of $7.26B.

How much cash does Bausch + Lomb have on hand?

Bausch + Lomb reported $536.29M in cash and cash equivalents in its most recent financial results.

What is Bausch + Lomb’s dividend yield?

Bausch + Lomb does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services